The latest news:

• Please help Us Better Understand Glioblastoma Multiforme (GBM) Patient Experiences through a short, online survey:         I sent this out a few weeks ago.. They need just a few more patients.  
  



• Clinical importance of eflornithine (difluoromethylornithine) for the treatment of malignant gliomas         This drug is in clinical trials now  for recurrent anaplastic astrocytoma.   This article reviews all of the data on over 500 patients who took the drug.  Looks best for anaplastic astrocytoma, where there was a big improvement in survival!  Disclosure: The company that makes this drug is a sponsor of the Musella Foundation
  



• ONC201 Trial Begins at NYU for Children with H3 K27M Mutant Glioma         This is an important trial for patients who have this mutation. Check your pathology report for the H3 K27M mutation, or if your child has a DIPG and did not have a biopsy - they most likely have this mutation.
  



• Final results of a phase I dose-escalation, dose-expansion study of adding disulfiram with or without copper to adjuvant temozolomide for newly diagnosed glioblastoma.         This sounded like a great idea, but unfortunately it did not pan out in this study.  That is why we can't just go by theory - it has to be tested in trials.  
  

BrainTumor Co-Payment Assistance Program Status:

• CLOSED to new applicants